RadNet, Inc. (RDNT)
| Market Cap | 5.65B -3.2% |
| Revenue (ttm) | 2.27B +18.9% |
| Net Income | -21.12M |
| EPS | -0.27 |
| Shares Out | 78.70M |
| PE Ratio | n/a |
| Forward PE | 123.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 528,179 |
| Open | 70.08 |
| Previous Close | 70.79 |
| Day's Range | 69.62 - 72.84 |
| 52-Week Range | 50.82 - 85.84 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 94.63 (+31.78%) |
| Est. Earnings | Nov 9, 2026 |
About RDNT
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RDNT stock is "Strong Buy." The 12-month stock price target is $94.63, which is an increase of 31.78% from the latest price.
News
RadNet Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Diagnostic imaging remains fragmented, offering significant consolidation opportunities. Stable Medicare reimbursement and strong commercial negotiations support growth, while technology and AI initiatives drive operational efficiency, new revenue streams, and improved capacity. Strategic partnerships and joint ventures with health systems are expanding, further accelerating growth.
RadNet Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Imaging and digital health segments are both experiencing strong growth, with digital health tools driving productivity and enabling new revenue streams. The unified operating system and expanding hospital partnerships position the company for continued margin expansion and market share gains, while disciplined M&A and AI innovation support a positive long-term outlook.
RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned an...
RadNet to Host Free Prostate Cancer Webinar on September 19, 2026
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a ne...
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned an...
RadNet participates in a conference call with KeyBanc
KeyBanc holds a conference call on PEAT Scan Growth Drivers with CFO Stolper on September 11.
RadNet price target raised to $79 from $65 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on RadNet (RDNT) to $79 from $65 and keeps an Overweight rating on the shares. The firm updated models in the…
RadNet price target raised to $94 from $90 at Truist
Truist raised the firm’s price target on RadNet (RDNT) to $94 from $90 and keeps a Buy rating on the shares. The firm remain bullish on RadNet post Q2 results…
RadNet Earnings Call Transcript: Q2 2026
Record revenue and adjusted EBITDA were driven by strong advanced imaging volumes, Digital Health growth, and recent acquisitions. Guidance for imaging center revenue, adjusted EBITDA, and free cash flow was raised, while Digital Health ARR and profitability continue to scale.
RadNet Earnings release: Q2 2026
RadNet released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
RadNet Quarterly report: Q2 2026
RadNet has published its Q2 2026 quarterly earnings report on August 10, 2026.
RadNet reports Q2 adjusted EPS 29c, consensus 20c
Reports Q2 revenue $622.7M, consensus $609.33M. Dr. Howard Berger, President and Chief Executive Officer of RadNet (RDNT), commented, “The Imaging Center and Digital Health reportable operating segmen...
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025 Revenue from the Digital Health reportable...
RadNet FDA clearance for DeepHealth an upside catalyst, says Jefferies
After RadNet (RDNT) announced receipt of FDA 510(k) clearance for its DeepHealth breast ultrasound AI-powered solution, Jefferies calls this out as “one of the catalysts we’ve previously identified” a...
RadNet’s DeepHealth reports FDA clearance for AI-powered breast ultrasound
DeepHealth, a wholly owned subsidiary of RadNet (RDNT), last night announced FDA 510(k) clearance for DeepHealth Breast Ultrasound, an AI-powered solution that it says “brings greater standardization,...
DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FD...
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and opera...
RadNet’s DeepHealth receives two FDA clearances
DeepHealth, a wholly owned subsidiary of RadNet (RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite functionalities: Breast Arterial Calcification Assessment, a tool appli...
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received...
RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services th...
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced t...
RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services th...
RadNet to Host Men's Health Webinar on June 13, 2026
RadNet hosts free webinar for Men's Health Month, featuring live Q&A and physicians presenting on coronary artery disease, prostate cancer and lung cancer.
RadNet price target lowered to $65 from $70 at Barclays
Barclays analyst Andrew Mok lowered the firm’s price target on RadNet (RDNT) to $65 from $70 and keeps an Overweight rating on the shares. The firm says RadNet is outperforming…